Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/27055
Title: | The Australia and New Zealand Cardio-Oncology Registry: evaluation of chemotherapy-related cardiotoxicity in a national cohort of paediatric cancer patients. | Authors: | Walker R.;Ayer J.;Gabriel M.;Walwyn T.;Saundankar J.;Forsey J.;Le H.;Mason K.;Celermajer D.;Downie P. ;Heath J.;Holland L.;Martin M.;McLeman L.;Diamond Y.;Marcocci M.;Donath S.;Cheung M.;Elliott D.A.;Conyers R.;La Gerche A.;Toro C.;Masango E.;Costello B.;Porello E.;Ludlow L.;Marshall G.;Trahair T.;Mateos M.;Lewin J.;Byrne J.;Boutros R.;Manudhane R.;Lapirow D. | Institution: | (Lapirow, La Gerche, Conyers) Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia (La Gerche, Costello) Cardiac Imaging Research, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (Toro, Ludlow, Martin, McLeman, Diamond, Elliott, Conyers) Children's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia (Masango, Porello, Ludlow, Le, Donath, Cheung, Elliott, Conyers) Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, VIC, Australia (Porello) Department of Physiology, The University of Melbourne, Melbourne, VIC, Australia (Marshall, Trahair, Mateos) Department of Pathology, University of New South Wales, Sydney, NSW, Australia (Mateos, Forsey) Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia (Lewin, Byrne, Boutros, Ayer, Gabriel, Forsey) Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia (Byrne) Discipline of Child and Adolescent Health, The University of Sydney, The Children's Hospital at Westmead, Sydney, NSW, Australia (Manudhane) The Michael Rice Centre, Women's and Children's Hospital, Adelaide, SA, Australia (Heath) Paediatric Oncology, Royal Hobart Hospital, Hobart, TAS, Australia (Walwyn, Saundankar) Oncology Department, Perth Children's Hospital, Perth, WA, Australia (Le) School of Health and Social Development, Deakin University, Melbourne, VIC, Australia (Mason) OnTrac@Petermac, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Mason) Clinical Haematology and Bone Marrow Transplant Service, The Royal Melbourne Hospital, Melbourne, VIC, Australia (Celermajer) Cardiology Department, The Royal Prince Alfred Hospital, Sydney, NSW, Australia (Celermajer) Faculty of Health and Medicine, The University of Sydney, Sydney, NSW, Australia (Downie) Children's Cancer Centre, Monash Health, Monash Children's Hospital, Melbourne, VIC, Australia (Walker, Holland) Oncology Unit, Queensland Children's Hospital, Brisbane, QLD, Australia (Marcocci) Chair, My Room Children's Cancer Charity, Melbourne, VIC, Australia (Cheung) Department of Cardiology, The Royal Children's Hospital, Melbourne, VIC, Australia (Elliott) Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia | Issue Date: | 9-Mar-2021 | Copyright year: | 2021 | Publisher: | Blackwell Publishing | Place of publication: | Australia | Publication information: | Internal Medicine Journal. 51 (2) (pp 229-234), 2021. Date of Publication: February 2021. | Journal: | Internal Medicine Journal | Abstract: | Cancer therapy related cardiac dysfunction (CTRCD) is an area of increasing focus, particularly during the survivorship period, for paediatric, adolescent and adult cancer survivors. With the advent of immunotherapy and targeted therapy, there is a new set of mechanisms from which paediatric and young adult patients with cancer may suffer cardiovascular injury. Furthermore, cardiovascular disease is the leading cause of morbidity and mortality in the survivorship period. The recently established Australian Cardio-Oncology Registry is the largest and only population-based cardiotoxicity database of paediatric and adolescent and young adult oncology patients in the world, and the first paediatric registry that will document cardiotoxicity caused by chemotherapy and novel targeted therapies using a prospective approach. The database is designed for comprehensive data collection and evaluation of the Australian practice in terms of diagnosis and management of CTRCD. Using the Australian Cardio-Oncology Registry critical clinical information will be collected regarding predisposing factors for the development of CTRCD, the rate of subclinical left ventricular dysfunction and transition to overt heart failure, further research into protectant molecules against cardiac dysfunction and aid in the discovery of which genetic variants predispose to CTRCD. A health economic arm of the study will assess the cost/benefit of both the registry and cardio-oncology clinical implementation. Finally, an imaging arm will establish if exercise cardiac magnetic resonance imaging and VO2 max testing is a more sensitive predictor of cardiac reserve in paediatric and adolescent and young adult oncology patients exposed to cardiac toxic therapies.Copyright © 2019 Royal Australasian College of Physicians | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/imj.14719 |
PubMed URL: | 31841257 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31841257] | ISSN: | 1444-0903 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/27055 | Type: | Article | Subjects: | imatinib/dt [Drug Therapy] imatinib/pv [Special Situation for Pharmacovigilance] lapatinib/ae [Adverse Drug Reaction] lapatinib/dt [Drug Therapy] lapatinib/pv [Special Situation for Pharmacovigilance] sorafenib/dt [Drug Therapy] sorafenib/pv [Special Situation for Pharmacovigilance] sunitinib/ae [Adverse Drug Reaction] sunitinib/dt [Drug Therapy] sunitinib/pv [Special Situation for Pharmacovigilance] trastuzumab/ae [Adverse Drug Reaction] trastuzumab/dt [Drug Therapy] trastuzumab/pv [Special Situation for Pharmacovigilance] valrubicin/ae [Adverse Drug Reaction] valrubicin/dt [Drug Therapy] valrubicin/pv [Special Situation for Pharmacovigilance] sorafenib/ae [Adverse Drug Reaction] adolescent adult article Australia *cancer chemotherapy *cardiology *cardiotoxicity/di [Diagnosis] *cardiotoxicity/si [Side Effect] cardiovascular magnetic resonance child *childhood cancer/dt [Drug Therapy] clinical practice cohort analysis disease course disease predisposition *drug safety genetic variability groups by age health economics heart failure heart left ventricle failure human infant information processing maximal oxygen uptake New Zealand newborn *oncology predictor variable priority journal bevacizumab/ae [Adverse Drug Reaction] bevacizumab/dt [Drug Therapy] bevacizumab/pv [Special Situation for Pharmacovigilance] daunorubicin/ae [Adverse Drug Reaction] daunorubicin/dt [Drug Therapy] daunorubicin/pv [Special Situation for Pharmacovigilance] doxorubicin/ae [Adverse Drug Reaction] doxorubicin/dt [Drug Therapy] doxorubicin/pv [Special Situation for Pharmacovigilance] epirubicin/ae [Adverse Drug Reaction] epirubicin/dt [Drug Therapy] epirubicin/pv [Special Situation for Pharmacovigilance] idarubicin/ae [Adverse Drug Reaction] idarubicin/dt [Drug Therapy] idarubicin/pv [Special Situation for Pharmacovigilance] imatinib/ae [Adverse Drug Reaction] disease course disease predisposition *drug safety genetic variability groups by age health economics heart failure heart left ventricle failure human infant information processing maximal oxygen uptake New Zealand newborn *oncology predictor variable priority journal Article adolescent adult Australia *cancer chemotherapy *cardiology *cardiotoxicity / *diagnosis / *side effect cardiovascular magnetic resonance child *childhood cancer / *drug therapy clinical practice cohort analysis |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.